GNI Group 

GNI Group Ltd. engages in the research, development, manufacture, and sale of pharmaceutical drugs in Japan and internationally. The company offers Etuary for the treatment of idiopathic pulmonary fibrosis. It is also developing Etuary, which is in Phase III clinical trial for the treatment of connective tissue-associated interstitial lung disease; and in clinical trial pre-phase III clinical trial pilot study for the treatment of radiation pneumonitis, as well as for the treatment of diabetic nephropathy. In addition, the company is involved in developing F351, which is in Phase III clinical trial for the treatment of liver fibrosis; and F573, which is in phase II for the treatment of acute chronic liver failure. Further, it is developing F528, which is in Phase 2 clinical trial for Chronic Obstructive Pulmonary Disease; and F230, which is in clinical trial for Pulmonary Arterial Hypertension. GNI Group Ltd. was incorporated in 2001 and is headquartered in Tokyo, Japan.